Feature|Articles|March 13, 2024
- Pharmaceutical Executive: March 2024
- Volume 44
- Issue 3
Pharmaceutical Executive: March 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
How’s Business?almost 2 years ago
Eyeing Efficiency for Allalmost 2 years ago
Positioning Medical Information as a Trust Driver for Your Brandalmost 2 years ago
Straight and Simple Advice Lives On in the Pharma Industryalmost 2 years ago
A Return to the Fundamentals in Biotech Investment?almost 2 years ago
The Shifting Landscape of the Life Sciences Job Marketalmost 2 years ago
Copay Adjustment Programs: What’s Next for Manufacturers?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
2
JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade
3
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
4
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
5